Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.43 |
| ▸ | OPRL1 | P41146 | 8/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 7/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 7/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4229239 | 0.84 | HRH3 (0.44) | HRH3OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL4238390 | 0.79 | DRD2 (0.46) | HRH3CYP2D6KDM4ELMNAMAPT | |
| SCHEMBL4233587 | 0.78 | OPRL1 (0.59) | OPRL1KDM4E | |
| SCHEMBL3295263 | 0.77 | HRH3 (0.40) | HRH3CYP2D6KDM4ELMNAMAPT | |
| SCHEMBL471858 | 0.74 | KDM4E (0.60) | HRH3CYP2D6KDM4ELMNAMAPT | |
| SCHEMBL25453172 | 0.72 | OPRL1 (0.65) | OPRL1OPRM1OPRD1OPRK1CYP2D6 | |
| SCHEMBL24422204 | 0.72 | CYP2D6 (0.58) | OPRL1OPRM1OPRD1OPRK1CYP2D6 | |
| SCHEMBL10057646 | 0.70 | OPRM1 (0.63) | OPRL1OPRM1OPRD1OPRK1CYP2D6 | |
| SCHEMBL23901648 | 0.70 | OPRL1 (0.63) | OPRL1OPRM1OPRD1OPRK1CYP2D6 | |
| SCHEMBL5962422 | 0.70 | OPRM1 (0.63) | OPRL1OPRM1OPRD1OPRK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| EP-1879887-A2 | NPY ANTAGONISTS, PREPARATION AND USE | Cerep (FR) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006108965-A2 | NPY ANTAGONISTS, PREPARATION AND USE | CEREP (FR) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | NPY1R, NPY5R, NPY2R | HRH3 210/4885OPRL1 19/4885OPRM1 179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.